Purpose of Study:
To demonstrate superiority of macitentan 75 mg in prolonging the time to the first Clinical Events Committee (CEC)- adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg
Study Dates:
June 30, 2020 - February 20, 2029
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Sponsors:
Actelion Pharmaceuticals Ltd*
ClinicalTrails.gov Identifier:
NCT04273945
